Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

TPR100: UK Regulatory Submission

Futura Medical
Posted on: 23 Jul 18

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that its UK commercialisation partner for TPR100, one of the Company’s novel topical pain relief products, has filed the product’s marketing authorisation application with the UK Medicines and Healthcare products Regulatory Agency.


TPR100 is licensed in the UK to Thornton & Ross, one of the UK’s largest consumer healthcare companies and a subsidiary of STADA. Thornton & Ross holds exclusive rights to manufacture, distribute and market TPR100 in the UK for the lifetime of the product’s patents, which run to 2028 in the UK.


TPR100, which benefits from the rapid skin permeation rates offered by Futura’s proprietary DermaSys® delivery system, will be launched, once approved, as an over-the-counter and general sales ledger product for the local symptomatic relief of pain and inflammation in:

  •  trauma of the tendons, ligaments, muscles and joints, e.g. from sprains, strains and bruises
  • localised forms of soft tissue rheumatism.


Futura has achieved statistically significant pain relief in a clinical study compared with placebo for TPR100, which is a non-steroidal anti-inflammatory drug (“NSAID”) using diclofenac as its active ingredient.


James Barder, Chief Executive of Futura Medical, said: “The filing of this marketing authorisation application marks a very important step in the commercialisation of TPR100 in the UK. We are delighted by the commitment to the product shown by Thornton & Ross and we look forward to the product’s launch in due course.


“TPR100 has the potential to be a best-in-class treatment in which the topical formulation and efficacy profile very successfully meet patient needs. We continue in commercial discussions with several potential distribution partners for territories outside of the UK.”



For any further information please contact:



Futura Medical plc


James Barder, Chief Executive


Tel: +44 (0)1483 685 670

mail to:




N+1 Singer (Nominated Adviser and Broker)


Aubrey Powell / Liz Yong


Tel:+44 (0) 20 7496 3000



For media enquiries please contact:





Mark Court / Sophie Wills / Tilly Abraham

Tel: +44 (0)20 7466 5000

Editor's Details

Mike Wood

Last updated on: 23/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.